Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...
Google DeepMind’s strategy chief says the industry’s trillion-dollar AI buildout is a bet on recursive self-improvement: AI that makes better AI. He also admits today’s revenue cannot justify the ...
Jeff Dean, one of the longest-serving and most influential executives at Google, is stepping down from the search giant to launch his own AI startup. Coming with him as co-founders are several other ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Chad Schuster discusses bridging Python's ...
Face ID and fingerprints are convenient, but law enforcement can bypass them much more easily than a passcode. Here's why you should go back to basics to improve your privacy and security. I review ...
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.41 per share a year ago. These ...
You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Wall Street is betting big on, and pouring billions into, AI, as big banks jostle to remain ahead of ...
Recursion Pharmaceuticals Inc. has disclosed IND clearance for REC-7735, its AI-designed PI3Kα H1047R inhibitor, in its quarterly earnings report. A phase I/II trial for patients with select PIK3CA ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results